{"name":"MacroGenics, Inc.","slug":"macrogenics","ticker":"MGNX","exchange":"NASDAQ","domain":"macrogenics.com","description":"MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell e","hq":"Rockville, MD","founded":0,"employees":"293","ceo":"Scott Koenig","sector":"Biotech","stockPrice":3.34,"stockChange":-0.01,"stockChangePercent":-0.3,"marketCap":"$212M","metrics":{"revenue":149500000,"revenueGrowth":113,"grossMargin":-22.5,"rdSpend":147172000,"netIncome":-74620000,"cash":189912992,"dividendYield":0,"peRatio":-3.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"MGD010","genericName":"MGD010","slug":"mgd010","indication":"Other","status":"phase_1"},{"name":"Enoblituzumab Schedule 2","genericName":"Enoblituzumab Schedule 2","slug":"enoblituzumab-schedule-2","indication":"Other","status":"phase_1"},{"name":"MGC028","genericName":"MGC028","slug":"mgc028","indication":"Other","status":"phase_1"},{"name":"enoblituzumab plus ipilimumab","genericName":"enoblituzumab plus ipilimumab","slug":"enoblituzumab-plus-ipilimumab","indication":"Other","status":"phase_1"},{"name":"obrindatamab","genericName":"obrindatamab","slug":"obrindatamab","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Hepatitis A vaccine","genericName":"Hepatitis A vaccine","slug":"hepatitis-a-vaccine","indication":"Prevention of hepatitis A infection in adults and children","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Physician's choice of chemotherapy.","genericName":"Physician's choice of chemotherapy.","slug":"physician-s-choice-of-chemotherapy","indication":"Control arm in phase 3 oncology trials (specific indication depends on trial protocol)","status":"phase_3"}]}],"pipeline":[{"name":"MGD010","genericName":"MGD010","slug":"mgd010","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Enoblituzumab Schedule 2","genericName":"Enoblituzumab Schedule 2","slug":"enoblituzumab-schedule-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Hepatitis A vaccine","genericName":"Hepatitis A vaccine","slug":"hepatitis-a-vaccine","phase":"marketed","mechanism":"Hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.","indications":["Prevention of hepatitis A infection in adults and children"],"catalyst":""},{"name":"MGC028","genericName":"MGC028","slug":"mgc028","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Physician's choice of chemotherapy.","genericName":"Physician's choice of chemotherapy.","slug":"physician-s-choice-of-chemotherapy","phase":"phase_3","mechanism":"This is a placeholder term referring to standard chemotherapy regimens selected by the treating physician, rather than a specific drug entity.","indications":["Control arm in phase 3 oncology trials (specific indication depends on trial protocol)"],"catalyst":""},{"name":"enoblituzumab plus ipilimumab","genericName":"enoblituzumab plus ipilimumab","slug":"enoblituzumab-plus-ipilimumab","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"obrindatamab","genericName":"obrindatamab","slug":"obrindatamab","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"MacroGenics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"MacroGenics reported its fourth quarter and full year 2023 financial results, with revenue of $23.4 million and a net loss of $64.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"MacroGenics Announces Collaboration with Incyte to Develop and Commercialize Tebotelimab","summary":"MacroGenics announced a collaboration with Incyte to develop and commercialize tebotelimab, a monoclonal antibody for the treatment of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Fast Track Designation to Tebotelimab for the Treatment of Solid Tumors","summary":"The FDA granted fast track designation to tebotelimab for the treatment of solid tumors, a significant milestone for the company's pipeline candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOMy1kSF96bDFUSVd3UXpUWWRBR091UlZzYWxGclZvdGZxTUFGT1VoTTg1bnpJdy1aOTdTdmhsWk9GRUFjanJnWGZhaWFwWjQ0RjBZN2VjZXhZb3FwZFNoX0cyU0Z5R1hVcWRmalRUSDVlTHVBcUFZaGFUczhlcF9vbW9WTjh1WlVab0ZwMGE4UnZEUWdUN1EyczVFYlFNcUhPdzlvanpB?oc=5","date":"2026-02-26","type":"pipeline","source":"Stock Titan","summary":"Cancer drug developer MacroGenics lines up March investor talks - Stock Titan","headline":"Cancer drug developer MacroGenics lines up March investor talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNZi1ualFzWVoxNzJGOVA2bUk0bFQzX1pxSFA2VWpLbWlPYThQNzZmcGt0Q2w1WWo0bXpmQ3ptOUs5OUhRMkxSRTFnMmhIMkxoejVsWXRJcVd5bFB1NjV6Z0QtQ19FV0huZktRdXpJS1ljRjhubHl5a1Z5TUZsLWZKREJ3S2Q?oc=5","date":"2026-02-24","type":"regulatory","source":"Seeking Alpha","summary":"MacroGenics drops after FDA partial clinical hold on lead program - Seeking Alpha","headline":"MacroGenics drops after FDA partial clinical hold on lead program","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNNDZaendZcThSbWs5bGY2SDk5allYVFZLNHFubTJQVlJieWYtdW04UnFESzd3VzJiYzY2SG5sejE3Y1A3aWV3MXdwU2hPdWJEZjFhTnVOQ3QybjVYa2hudFN5RnJMNFBHelN3bk5Kc2Z0c0NzS2lVX19scUJFdFUyczRzQmdrMmF0aTU3RkFLUGZudVhPWUs2ag?oc=5","date":"2026-01-13","type":"regulatory","source":"Finviz","summary":"Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz","headline":"Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-01-06","type":"earnings","source":"simplywall.st","summary":"There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st","headline":"There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQQTZ1ZG5CU05kNkhjUTNGMm5wWU5fN29XZnRnRWVjS282M2g4LTN0bkpYamJUbjFweUhVSmcwQjQ1LV9TLVdlVWtyOTBOT19GVmpLWHVudEtOY3M3NjRMMkJtTjNReXB5Q21PaWwyVk5lQU1HWDBxd084REpxS2hqbWpVamNlRnNmUkJNR1BWWTB5M2pLUFI1OV9YZzJUa0VWV1VuZUF4Z1NXb05pdkZzUEZFZHVEcUpKRDdueEtXU0xrTGRDVm50S3hlOUYtZDJFT19fYXVFcmJUQ3ZNaXfSAeMBQVVfeXFMTkYtYUM2OHdJU1NNUFJvaXBVLU1Jc0pUelYtRmxWU1R5WjhVYjJKNzVlOXJ0S0tuLXM2a1Y2M3FJNE1Md0JIU3l0ZVdPejhGalBXZVhId25wLXpLQWp1YmdvcHBmNC0zd09UTU9KOW1WZWxBeVRhaC1tN0YyTHk4dDJQY0dmYkpHck5udHpsdGdqQXNtUHVrYWYyRlRJZ28wY2V0UHh0WFU5c2lFUzVvQ1FOQURBYTZncTRSZk9XZVBwYk5PYlpEWnRWdE9iaGEtZjR6R21JNDFBYm1xNU5qVkxaX2s?oc=5","date":"2025-10-22","type":"pipeline","source":"simplywall.st","summary":"MacroGenics, Inc. (NASDAQ:MGNX) institutional owners may be pleased with recent gains after 49% loss over the past year - simplywall.st","headline":"MacroGenics, Inc. (NASDAQ:MGNX) institutional owners may be pleased with recent gains after 49% loss over the past year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOQXRDaVFtZzZKcEl5ODgtVHBrRDk4VkNfaDB2TDJlMnJYcDFqUHpGTkZONndSS0NOWUFJbWhhbnhZWE9ILURMSE9aLWRDdDkzbTVPOFQ4c3NMbmlxaG4tdkNJVXl4VHk0Q2JTVS13d2VJWVEwLTl5UTBkeGJuOU94MC0zZXFLU1pIMl9LSjBNS2ZnRy1WM1EtUnpBaXRqdHJWeHJQcEVJWXZBVEMzT3c?oc=5","date":"2025-08-16","type":"pipeline","source":"The MoCo Show -","summary":"Rockville’s MacroGenics Appoints New President/CEO For First Time in 24 Years - The MoCo Show -","headline":"Rockville’s MacroGenics Appoints New President/CEO For First Time in 24 Years - The MoCo Show -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMDAwLUFvZ3ppOVVNOThhT0FZRlNuN2MxaEUwM2I4a1hHeFlBLVVfNkJzQ2Y0dDZDMW9yS0FNMUlUc1B1Qnc5bW9NdVI0MDY5SFdGQzNZMHRzTlIwUkVnaDh0RVNrY29fSUlJMUt3Q0FmNDkybUxuZTdqREZsaGllbU4tUXdHRDZEZmJua2tVVlFPbVBKM2ZTeGp4U1p4aGFDYnYzX3JCVWY?oc=5","date":"2025-08-15","type":"pipeline","source":"BioBuzz","summary":"People on the Move: Eric Risser Appointed President & CEO of MacroGenics - BioBuzz","headline":"People on the Move: Eric Risser Appointed President & CEO of MacroGenics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-21","type":"pipeline","source":"simplywall.st","summary":"Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher - simplywall.st","headline":"Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQeHN0di1FMU1lQzhrbTR4a2lPc0NMWU1NN0Z4OW93LVd4NHVjOUYxcXpXUDJ6aTZhQ2VKSUJQWnFFVzMzVmZYQURKc3R1dTlZSXJHcVB6dUtrMDBmMS1pZG9YM25vX29jemVOTWExOXc3S0o3M090UWdrSXZnZGFQR1FaWE45S001M1lya1ZiOUpyYUEtekltcHV2MGV2cnhmZXNZX3ZBMDBxQ19KQ3ZRY0R6UkEwYkQydFkydl83SDBaWGk3LVRsMmpPREYybVd2XzRHZg?oc=5","date":"2025-05-06","type":"earnings","source":"globenewswire.com","summary":"MacroGenics Announces Date of First Quarter 2025 Financial Results - globenewswire.com","headline":"MacroGenics Announces Date of First Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1wRnI5aGpSTVhSa2gxSXFnN2Z5S3BBX3Blam9iWmcxWlpkZXRYdHJmeHFQdjNNVTh5NnFZc085dkhSRzFPODhuT2l6YTJjazN2dF9z?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"MEIP Stock Price, News & Analysis - Stock Titan","headline":"MEIP Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5sMHlWck1vOWJTYWJoNkU3aGhwaFJ0MTVMdEhfaVpGNWxqb2RLb1pSZVFzS2VRbm41TEFFNzJnVHNrcFdSYjZFRVZwS1ZTV1FkUnAtUFJpLVoxSXg2?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"MGNX Stock Price and Chart — NASDAQ:MGNX - TradingView","headline":"MGNX Stock Price and Chart — NASDAQ:MGNX","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":5,"marketed":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":149500000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":149500000,"period":"2025-12-31"},{"value":149962000,"period":"2024-12-31"},{"value":149962000,"period":"2024-12-31"},{"value":58749000,"period":"2023-12-31"},{"value":58749000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":147172000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74620000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":256846000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.34,"previousClose":3.35,"fiftyTwoWeekHigh":3.54,"fiftyTwoWeekLow":1.02,"fiftyTwoWeekRange":"1.02 - 3.54","fiftyDayAverage":2.3,"twoHundredDayAverage":1.77,"beta":1.1,"enterpriseValue":59761052,"forwardPE":-3.4,"priceToBook":3.8,"priceToSales":1.42,"enterpriseToRevenue":0.4,"enterpriseToEbitda":-0.91,"pegRatio":0,"ebitda":-65669000,"ebitdaMargin":-43.9,"freeCashflow":-58232124,"operatingCashflow":-81040000,"totalDebt":36762000,"debtToEquity":66.1,"currentRatio":5.1,"returnOnAssets":-17.6,"returnOnEquity":-86.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":5,"targetMeanPrice":3.6,"targetHighPrice":5,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.1,"institutionHeldPercent":64.6,"sharesOutstanding":63555837,"floatShares":55591655,"sharesShort":3975110,"shortRatio":2.54,"shortPercentOfFloat":6.2,"epsTrailing":-1.18,"epsForward":-0.97,"revenuePerShare":2.37,"bookValue":0.88,"officers":[{"age":58,"name":"Mr. James  Karrels","title":"Senior VP, CFO & Corporate Secretary"},{"age":52,"name":"Mr. Eric Blasius Risser","title":"CEO, President & Director"},{"age":58,"name":"Dr. Thomas M. Spitznagel Ph.D.","title":"Senior Vice President of Technical Operations"},{"age":71,"name":"Dr. Ezio  Bonvini M.D.","title":"Senior VP of Research & Chief Scientific Officer"},{"age":54,"name":"Mr. Jeffrey Stuart Peters J.D.","title":"Senior VP, General Counsel & Corporate Compliance Officer"},{"age":null,"name":"Mr. Steve  Harig","title":"Senior Vice President of Human Resources"},{"age":null,"name":"Mr. Harish  Krishnaswamy","title":"Senior Vice President of Business Development & Portfolio Planning"},{"age":61,"name":"Dr. Frank George Perabo FEBU, M.D., Ph.D.","title":"Vice President & Interim Head of Clinical Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.macrogenics.com","phone":"301 251 5172"}}